Investor Relations

Corporate ProfileNuvectra® is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge, neural-interface technologies for the neuroscience pre-clinical research market.

On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.

Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."


Stock Quote NVTR (Common Stock) $14.260.00 (0.00%)
ExchangeNASDAQ
Volume0
Today's Open$0.00
Previous Close$14.26
Data as of 01/22/19 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NVTR.O.  Currently trading at $14.26 with a 52 week high of $25.17 and a 52 week low of $7.87.

Recent News

January 07, 2019

Nuvectra® Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue

PLANO, Texas, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2018. Preliminary unaudited consolidated revenue in the fourth quarter of 2018 is expected to be in the range of $15.3 to $15.7 million, compared to $12.0 million in the fourth quarter of 2017. Preliminary unaudited Algovita revenue in the fourth quarter of 2018 is

Read More >

January 02, 2019

Nuvectra Announces Divesture of NeuroNexus Subsidiary

PLANO, Texas, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has entered into an agreement effective December 31, 2018, to sell its wholly owned subsidiary NeuroNexus Technologies, Inc. (“NeuroNexus”) to NEL Group, Inc., an entity affiliated with certain former employees of NeuroNexus, for $5.0 million in cash. NeuroNexus will operate as a separate entity following the sale. NeuroNexus designs, manufactu

Read More >


Investor Contact

The Ruth Group
Brian Johnston
Tram Bui
investors@nuvectramed.com

Events
There are currently no events scheduled.